Our scientists work with a simple purpose - find the unmet needs in
chronic disease and translate them into new therapeutic solutions. One
of those ideas is advancing type 2 diabetes treatment from injections
This has been a goal for many years, but the challenge has been the
body’s digestive system. Once swallowed, biological medicines, like
insulin, are digested by enzymes in the body, the same way food is
broken down. We needed to find a way for biological medicines to get
through the digestive system intact and get into the blood.
We have recently succeeded and shown that a synthetic version of the
glucagon-like peptide-1 (GLP-1) hormone can be taken in a tablet. The
GLP-1 hormone is naturally produced in the gut and gets released in
response to food. When released, GLP-1 stimulates insulin production
in the pancreas, which again lowers the amount of glucose in the blood.
This is the world’s first oral treatment for type 2 diabetes with a
GLP-1 receptor agonist. We hope that it will not be too long before we
will be able to offer a broader range of oral treatments. Not only for
diabetes, but for the other serious chronic diseases in our research portfolio.